-
Article
Open AccessOvercoming challenges in the economic evaluation of interventions to optimise antibiotic use
Bacteria are becoming increasingly resistant to antibiotics, reducing our ability to treat infections and threatening to undermine modern health care. Optimising antibiotic use is a key element in tackling the...
-
Article
Open AccessWhat Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK
Decisions on funding new healthcare technologies assume that all health improvements are valued equally. However, public reaction to health technology assessment (HTA) decisions suggests there are health attri...
-
Article
Open AccessPreferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom
In the UK, consultations for prescription medicines are available via private providers such as online pharmacies. However, these providers may have lower thresholds for prescribing certain drugs. This is a pa...
-
Article
Open AccessWhy do hospital prescribers continue antibiotics when it is safe to stop? Results of a choice experiment survey
Deciding whether to discontinue antibiotics at early review is a cornerstone of hospital antimicrobial stewardship practice worldwide. In England, this approach is described in government guidance (‘Start Smar...
-
Article
Open AccessMind the gap? The platform trial as a working environment
Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials...
-
Article
Open AccessCorrection to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
.
-
Article
Open AccessWill the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
One of the functions of the reformed Cancer Drugs Fund in England is as a managed access fund, providing conditional funding for cancer drugs where there is uncertainty in the economic case, and where that unc...
-
Article
Open AccessCancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
The Scottish Medicines Consortium evaluates new drugs for use in the National Health Service in Scotland. Reforms in 2014 to their evaluation process aimed to increase patient access to new drugs for end-of-li...
-
Article
Open AccessDoes the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics
Policies such as the Cancer Drugs Fund in England assumed a societal preference to fund cancer care relative to other conditions, even if that resulted in lower health gain for the population overall.
